Hematopoietic stem cell transplantation for the management of follicular lymphoma

References

• ArmitageJOWeisenburgerDDNew approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification ProjectJ Clin Oncol1998168278027959704731
   PubMed Web of Science ®Google Scholar
• JohnsonPWRohatinerAZWhelanJSPatterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single centerJ Clin Oncol19951311401477799014
   PubMed Web of Science ®Google Scholar
• HorningSJFollicular lymphoma: Have we made any progress?Ann Oncol200011Suppl 1232710707774
   PubMed Web of Science ®Google Scholar
• FisherRILeBlancMPressOWMaloneyDGUngerJMMillerTPNew treatment options have changed the survival of patients with follicular lymphomaJ Clin Oncol200523338447845216230674
   PubMed Web of Science ®Google Scholar
• SwensonWTWooldridgeJELynchCFForman-HoffmanVLChrischillesELinkBKImproved survival of follicular lymphoma patients in the United StatesJ Clin Oncol200523225019502615983392
   PubMed Web of Science ®Google Scholar
• CzuczmanMSWeaverRAlkuzwenyBBerlfeinJGrillo-LopezAJProlonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-upJ Clin Oncol200422234711471615483015
   PubMed Web of Science ®Google Scholar
• VidalLGafter-GviliALeiboviciLShpilbergORituximab as maintenance therapy for patients with follicular lymphomaCochrane Database Syst Rev20092CD00655219370640
   PubMed Web of Science ®Google Scholar
• MorschhauserFRadfordJVan HoofAPhase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaJ Clin Oncol200826325156516418854568
   PubMed Web of Science ®Google Scholar
• GyanEFoussardCBertrandPHigh-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 yearsBlood20091135995100118955565
   PubMed Web of Science ®Google Scholar
• GopalAKGooleyTAMaloneyDGHigh-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysisBlood200310272351235712750161
   PubMed Web of Science ®Google Scholar
• TarellaCZanniMMagniMRituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: A multicenter Gruppo Italiano Terapie Innnovative nei linfomi surveyJ Clin Oncol200826193166317518490650
   PubMed Web of Science ®Google Scholar
• VosoMTPantelGWeisMIn vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin‘s lymphomaBr J Haematol2000109472973510929022
   PubMed Web of Science ®Google Scholar
• HorowitzMMGaleRPSondelPMGraft-versus-leukemia reactions after bone marrow transplantationBlood19907535555622297567
   PubMed Web of Science ®Google Scholar
• GaleRPChamplinREHow does bone-marrow transplantation cure leukaemia?Lancet19842839328306145942
   PubMed Web of Science ®Google Scholar
• WeidenPLFlournoyNSandersJESullivanKMThomasEDAnti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantationTransplant Proc1981131 Pt 12482517022833
   PubMed Web of Science ®Google Scholar
• van BesienKWde LimaMGiraltSAManagement of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effectBone Marrow Transplant199719109779829169641
   PubMed Web of Science ®Google Scholar
• RondonGGiraltSHuhYGraft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemiaBone Marrow Transplant19961836696728879640
   PubMed Web of Science ®Google Scholar
• KolbHJSchattenbergAGoldmanJMGraft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patientsBlood1995865204120507655033
   PubMed Web of Science ®Google Scholar
• van BesienKLoberizaFRJrBajorunaiteRComparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphomaBlood2003102103521352912893748
   PubMed Web of Science ®Google Scholar
• HosingCSalibaRMMcLaughlinPLong-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphomaAnn Oncol200314573774412702528
   PubMed Web of Science ®Google Scholar
• KhouriIFSalibaRMGiraltSANonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortalityBlood200198133595359911739162
   PubMed Web of Science ®Google Scholar
• AntinJHFerraraJLCytokine dysregulation and acute graft-versus-host diseaseBlood19928012296429681467511
   PubMed Web of Science ®Google Scholar
• HillGRCrawfordJMCookeKRBrinsonYSPanLFerraraJLTotal body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokinesBlood1997908320432139376604
   PubMed Web of Science ®Google Scholar
• IngramWDevereuxSDas-GuptaEPOutcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphomaBr J Haematol2008141223524318318762
   PubMed Web of Science ®Google Scholar
• KhouriIFMcLaughlinPSalibaRMEight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabBlood2008111125530553618411419
   PubMed Web of Science ®Google Scholar
• van BesienKSobocinskiKARowlingsPAAllogeneic bone marrow transplantation for low-grade lymphomaBlood1998925183218369716615
   PubMed Web of Science ®Google Scholar
• SurboneAArmitageJOGaleRPAutotransplantation in lymphoma: Better therapy or healthier patients?Ann Intern Med199111412105910602029103
   PubMed Web of Science ®Google Scholar
• RohatinerAZNadlerLDaviesAJMyeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-upJ Clin Oncol200725182554255917515573
   PubMed Web of Science ®Google Scholar
• FreedmanASNeubergDMauchPLong-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphomaBlood199994103325333310552941
   PubMed Web of Science ®Google Scholar
• BiermanPJVoseJMAndersonJRBishopMRKessingerAArmitageJOHigh-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphomaJ Clin Oncol19971524454509053464
   PubMed Web of Science ®Google Scholar
• FreedmanASGribbenJGNeubergDHigh-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remissionBlood1996887278027868839876
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMSchiegnitzEMyeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study GroupBlood200410492667267415238420
   PubMed Web of Science ®Google Scholar
• MontotoSCanalsCRohatinerAZLong-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: An EBMT registry studyLeukemia200721112324233117637813
   PubMed Web of Science ®Google Scholar
• SchoutenHCKvaloySSydesMQianWFayersPMThe CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin’s lymphoma (NHL)Ann Oncol200011Suppl 1919410707787
   PubMed Web of Science ®Google Scholar
• SchoutenHCQianWKvaloySHigh-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: Results from the randomized European CUP trialJ Clin Oncol200321213918392714517188
   PubMed Web of Science ®Google Scholar
• ApostolidisJGuptaRKGrenzeliasDHigh-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-upJ Clin Oncol200018352753610653868
   PubMed Web of Science ®Google Scholar
• CaoTMHorningSNegrinRSHigh-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experienceBiol Blood Marrow Transplant20017529430111400952
   PubMed Web of Science ®Google Scholar
• ArcainiLMontanariFAlessandrinoEPImmunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphomaAnn Oncol20081971331133518344536
   PubMed Web of Science ®Google Scholar
• ArcainiLOrlandiEAlessandrinoEPA model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphomaBone Marrow Transplant200434217517915170171
   PubMed Web of Science ®Google Scholar
• SebbanCMounierNBrousseNStandard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA)Blood200610882540254416835383
   PubMed Web of Science ®Google Scholar
• SebbanCBricePDelarueRImpact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA studyJ Clin Oncol200826213614362018559872
   PubMed Web of Science ®Google Scholar
• RohatinerAZFreedmanANadlerLLimJListerTAMyeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphomaAnn Oncol19945Suppl 243146
   Google Scholar
• LadettoMDe MarcoFBenedettiFProspective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantageBlood200811184004401318239086
   PubMed Web of Science ®Google Scholar
• BuskeCHosterEDreylingMRituximab in combination with CHOP in patients with follicular lymphoma: Analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58 monthsBlood2008112901
   Web of Science ®Google Scholar
• HiddemannWBuskeCKnebaMAutologous stem cell transplantation after myeloablative therapy in first remission may be beneficial in patients with advanced stage follicular lymphoma after front-line therapy with R-CHOP. An analysis of two consecutive studies of the German Low Grade Lymphoma Study Group (GLSG)Blood2008112286287
   Google Scholar
• SteinRSGreerJPGoodmanSKallianpurAAhmedMSWolffSNHigh-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell originBone Marrow Transplant199923322723310084253
   PubMed Web of Science ®Google Scholar
• KuruvillaJPondGTsangRGuptaVLiptonJHMessnerHAFavorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphomaBiol Blood Marrow Transplant200814777578218541196
   PubMed Web of Science ®Google Scholar
• van BesienKCarrerasJBiermanPJUnrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: Long-term outcomesBiol Blood Marrow Transplant200915555456319361747
   PubMed Web of Science ®Google Scholar
• LaportGCBTomblynMRKahlBSon behalf of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-Hodgkins lymphoma (FL) beyond first complete response or first partial responseJ Clin Oncol200826382a
   Web of Science ®Google Scholar
• VerdonckLFDekkerAWLokhorstHMPetersenEJNieuwenhuisHKAllogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphomaBlood19979010420142059354692
   PubMed Web of Science ®Google Scholar
• PeniketAJRuiz de ElviraMCTaghipourGAn EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantationBone Marrow Transplant200331866766812692607
   PubMed Web of Science ®Google Scholar
• RezvaniARStorerBMarisMNonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphomaJ Clin Oncol200826221121718056679
   PubMed Web of Science ®Google Scholar
• RodriguezRNademaneeARuelNComparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin’s lymphomaBiol Blood Marrow Transplant200612121326133417162215
   PubMed Web of Science ®Google Scholar
• HariPCarrerasJZhangMJAllogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioningBiol Blood Marrow Transplant200814223624518215784
   PubMed Web of Science ®Google Scholar
• RobinsonSPGoldstoneAHMackinnonSChemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow TransplantationBlood2002100134310431612393626
   PubMed Web of Science ®Google Scholar
• KusumiEKamiMKandaYReduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: A retrospective survey of 112 adult patients in JapanBone Marrow Transplant200536320521315937505
   PubMed Web of Science ®Google Scholar
• MorrisEThomsonKCraddockCOutcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin’s lymphomaBlood2004104133865387115304395
   PubMed Web of Science ®Google Scholar
• MorrisEMackinnonSOutcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin’s lymphoma (NHL)Transfus Apher Sci2005321738315737876
   PubMed Web of Science ®Google Scholar
• KhouriISalibaRGiraltSAllogeneic hematopoietic transplantation for indolent lymphomas: Improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimensBlood200096853a
   Google Scholar
• SorrorMLStorerBEMaloneyDGSandmaierBMMartinPJStorbROutcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemiaBlood2008111144645217916744
   PubMed Web of Science ®Google Scholar
• AviviIMontotoSCanalsCMatched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationBr J Haematol2009147571972819793383
   PubMed Web of Science ®Google Scholar
• BethgeWAWilburDSSandmaierBMRadioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantationLeuk Lymphoma20064771205121416923548
   PubMed Web of Science ®Google Scholar
• KangTYRybickiLABolwellBJEffect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphomaBone Marrow Transplant2007401097397817873917
   PubMed Web of Science ®Google Scholar
• VoseJMBiermanPJLoberizaFRLong-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: Effect of histological grade and Follicular International Prognostic IndexBiol Blood Marrow Transplant2008141364218158959
   PubMed Web of Science ®Google Scholar